Section 1 : GENERAL PRINCIPLES IN THERAPY 1. Ethnopharmacology 2. Reverse 3. Ecopharmacology 4. Translational pharmacology 5. Chronopharmacology 6. Spurious/falsely labelled/falsified/counterfeit 7. Off-label use of drug 8. Orphan drug 9. Over-the-counter 10. Generic drugs 11. Prodrugs 12. P-Drug concept 13. Rational use of drugs 14. Essential medicines – Indian context 15. Drug repositioning 16. Polypharmacy 17. Drug information centre 18. Pharmacoeconomic 19. errors 20. Pharmacovigilance 21. Haemovigilance 22. Materiovigilance 23. Vaccine vigilance 24. Drug therapy in geriatric population 25. Drug therapy in paediatric population 26. Drug therapy in pregnancy and lactation 27. Isomerism 28. Structural activity relationship (SAR) of sympathomimetics 29. Structural activity relationship (SAR) of corticosteroids 30. Structural activity relationship (SAR) of antipsychotics

Section 2 : TECHNIQUES IN 31. Bioinformatics 32. Proteomics 33. Metabolomics

Section 3 : DRUG DEVELOPMENT & CLINCIAL TRIAL 34. Contract research organization (CRO) 35. Good clinical practice (GCP) 36. Clinical trial design 37. Vaccine trial 38. Controls in clinical trials 39. Placebo in clinical trials 40. Bias in clinical trials 41. Blinding in clinical trials 42. Methods of randomization 43. Randomized controlled trials 44. Recommended format for a research protocol 45. Phase 0 trials/microdosing studies 46. Phase 1 protocol design 47. Clinical trials – Phases 48. Highlights of new drugs and clinical trial rules 2019 49. Institutional ethics committee (IEC) 50. Non-inferiority, superiority and equivalence trial – concept 51. N-of-1 clinical trial designs 52. Platform, umbrella and basket trials 53. Schedule Y 54. Approach to drug discovery and development

Section 4 : NON- 55. Toxicological screening 56. Committee for the purpose of control & supervision of experiments on animals (CPCSEA) 57. Hybridoma technology 58. Knockout mouse 59. Transgenic animal 60. Nude mouse 61. Toxin in drug development 62. Alternate to animal models 63. Modified Langendorff technique

Section 5 : ANIMAL SCREENING METHODS 64. Models for screening of anti-diabetic drugs 65. Models for screening of anti-hypertensive drugs 66. Models for screening of anti-epileptic drugs 67. Models for screening of anti-psychotic drugs 68. Models for screening of anti-depressant drugs 69. Models for screening of anti-parkinson drugs 70. Models for screening of nootrophic drugs 71. Models for screening of anti-anxiety drugs 72. Models for screening of anti-arrhythmic drugs 73. Models for screening of anti-anginal drugs 74. Models for screening of analgesic drugs 75. Models for screening of anti-inflammatory drugs 76. Models for screening of anti-ulcer drugs 77. Models for screening of muscle relaxant drugs 78. Models for screening of anti-fertility drugs 79. Models for screening of anti-cancer drgus 80. Models for screening of antioxidants

Section 6 : STATISTICS 81. Data 82. Central tendency 83. Standard deviation 84. Prevalence and incidence 85. The odds ratio and relative risk 86. Probability 87. Hypothesis testing 88. Type I & type II error 89. T Test 90. ANOVA 91. Chi square test 92. Parametric & nonparametric tests 93. Meta-analysis

Section 7 : ANALYTICAL BIOCHEMICAL ASSAYS 94. Enzyme-linked immunosorbent assay (ELISA) 95. Radioimmunoassay (RIA) 96. Fluorescence polarization immunoassay (FPIA) 97. Thin layer chromatography (TLC) 98. High-performance liquid chromatography (HPLC) 99. Polymerase chain reaction (PCR) 100. Mass spectrometry (MS) 101. Nuclear magnetic resonance (NMR) 102. High throughput screening (HTS) 103. Western blotting 104. Southern blotting 105. Spectrophotometry 106. Recombinant DNA technology 107. Limit tests in pharmaceuticals 108. Patch clamp technique 109. Therapeutic drug monitoring (TDM)

Section 8 : GENE AND DRUGS 110. Epigenetics 111. Pharmacogenetics and 112. Toxicogenomics Section 9 : PHARMACOTHERAPY 113. Drugs for obesity 114. Drugs for rheumatoid arthritis 115. Drugs for inflammatory bowel disease 116. Mushroom poisoning 117. Myasthenia gravis 118. Recent advances in insulin therapy 119. Management of heart failure

Section 10 : HISTORY 120. Renowned scientists in pharmacology 121. History of antibiotic 122. History of general anaesthesia

Section 11 : MISCELLANEOUS 123. Prebiotics and probiotics 124. Role of a pharmacologist 125. Critical appraisal of a journal article 126. Cell culture 127. Check points in cell cycle

Section 12 : RECENT ADVANCES 128. Tyrosine kinase inhibitors in cancer therapy 129. Immunotoxins 130. Monoclonal antibodies 131. Biosimilar 132. Targeted drug delivery 133. Carrier based novel drug delivery system 134. Newly approved drugs – 2019 135. Newly approved drugs – 2018 136. Newly approved drugs – 2017 137. Newly approved drugs – 2016 138. Newly approved vaccines (2011–2019) 139. Me-too drugs 140. Medical burnout 141. Adaptive designs in clinical trials 142. Coronavirus disease (Covid-19)

Index